rilzabrutinib
General
Pronunciation:
ril-za-broo-ti-nib
Trade Name(s)
- Wayrilz
Ther. Class.
none assigned
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Rilzabrutinib." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580140/all/rilzabrutinib.
Vallerand AHA, Sanoski CAC, . Rilzabrutinib. Davis's Drug Guide. F.A. Davis Company; 2025. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580140/all/rilzabrutinib. Accessed October 14, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Rilzabrutinib. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580140/all/rilzabrutinib
Vallerand AHA, Sanoski CAC, . Rilzabrutinib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 October 14]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580140/all/rilzabrutinib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - rilzabrutinib
ID - 3580140
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580140/all/rilzabrutinib
PB - F.A. Davis Company
ET - 19
DB - Pediatrics Central
DP - Unbound Medicine
ER -